SCHEMBL2826565

SCHEMBL2826565

Cc1cc(Nc2sc(C)nc2C(=O)O)on1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HCAR2 Q8TDS4 1/20 0.41
HTR2C P28335 2/20 0.41
GLA P06280 1/20 0.39
PKM P14618 1/20 0.39
EPHX2 P34913 1/20 0.38
GRM5 P41594 3/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.36
ATF1 P18846 1/20 0.36
NFKB1 P19838 1/20 0.36
SYK P43405 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5198757 0.83 GRM5 (0.32) ALDH1A1SMN1; SMN2GRM5LMNARECQL
SCHEMBL2826711 0.72 LMNA (0.41) ALDH1A1SMN1; SMN2GRM5LMNANTRK1
SCHEMBL2826274 0.71 GRM5 (0.46) SMN1; SMN2GRM5NTRK1NPC1RAB9A
SCHEMBL1896996 0.71 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2HCAR2HTR2CGLA
SCHEMBL2831124 0.71 GRM5 (0.64) GRM5KDM4ENTRK1NPC1RAB9A
SCHEMBL2828923 0.71 GRM5 (0.46) ALDH1A1SMN1; SMN2HCAR2GRM5KDM4E
SCHEMBL2832103 0.71 SMN1; SMN2 (0.46) SMN1; SMN2GRM5KDM4ENTRK1
SCHEMBL2829903 0.71 GRM5 (0.41) ALDH1A1SMN1; SMN2HCAR2GRM5KDM4E
SCHEMBL2826672 0.70 RAB9A (0.42) ALDH1A1SMN1; SMN2PKMTSHRLMNA
SCHEMBL5185015 0.70 L3MBTL1 (0.51) ALDH1A1SMN1; SMN2HCAR2HTR2CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP claimed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US claimed
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP disclosed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP disclosed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US disclosed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160857-A1 Thiazole-4-carboxyamide derivatives GRM1, GRM2, GRIA4 ALDH1A1 913/4885SMN1; SMN2 3071/4885HCAR2 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.